New research presented at the Society for Maternal-Fetal Medicine (SMFM) 2026 Pregnancy Meeting definitively states that receiving an mRNA COVID-19 vaccine shortly before or at any point during pregnancy is not associated with an increased risk of autism spectrum disorder (ASD) or other developmental concerns in children. This landmark investigation, offering robust long-term health data, addresses a significant public health concern and reinforces the safety profile of these vaccines for expectant mothers and their offspring, providing critical evidence to support vaccination recommendations for pregnant individuals worldwide. The Study Unveiled: Methodology and Findings The comprehensive investigation was meticulously conducted by researchers within the Maternal-Fetal Medicine Units Network, a collaborative research consortium dedicated to improving the health of mothers and children. The team embarked on a prospective, multi-center, and observational study that spanned nearly a year, from May 2024 to March 2025. This design allowed for real-time data collection and minimized recall bias, enhancing the reliability of the findings. The study population comprised 434 toddlers, carefully selected and assessed when they were between 18 months and 30 months of age, a crucial developmental window for identifying early signs of autism and other neurodevelopmental issues. To ensure a rigorous comparison, the cohort was divided into two equally sized groups: 217 children whose mothers received at least one dose of an mRNA COVID-19 vaccine either during pregnancy or within 30 days prior to conception, and a control group of 217 children born to mothers who did not receive an mRNA vaccine during the same critical period. "Our findings are remarkably reassuring for parents and healthcare providers," stated Dr. George R. Saade, MD, a senior researcher on the study and a distinguished Professor and Chair of Obstetrics and Gynecology, as well as Associate Dean for Women’s Health, at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA. Dr. Saade emphasized, "Neurodevelopment outcomes in children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy did not differ from those born to mothers who did not receive the vaccine, demonstrating no discernible link to autism or other developmental concerns." Rigorous Comparison of Developmental Outcomes To ensure the highest degree of accuracy and minimize confounding factors, the research team employed a sophisticated matching process. Vaccinated mothers were precisely paired with unvaccinated mothers based on several key demographic and clinical variables. These included the location of delivery (e.g., hospital, birth center), the exact date of delivery, insurance status, and maternal race. This meticulous pairing strategy helped to control for socioeconomic factors and healthcare access that might independently influence developmental outcomes. Furthermore, specific pregnancies were systematically excluded from both groups to enhance the homogeneity of the study population and focus on typical, full-term births. Exclusions included pregnancies that concluded before 37 weeks of gestation, those involving multiple births (e.g., twins, triplets), and cases where the child was diagnosed with a major congenital malformation. These exclusions ensured that the observed developmental patterns were more likely attributable to the presence or absence of maternal vaccination rather than other significant perinatal factors. The assessment of children’s development was multifaceted and employed standardized, widely validated screening tools. When the children reached 1.5 to 2.5 years of age, researchers administered the Ages and Stages Questionnaire Version 3 (ASQ-3). This comprehensive screening tool evaluates progress across five critical developmental domains: communication, gross motor skills, fine motor skills, problem-solving, and personal-social interaction. To provide an even more granular understanding of behavioral and developmental patterns, the research team also reviewed results from the Child Behavior Checklist (CBCL), the Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT-R/F), and the Early Childhood Behavior Questionnaire (ECBQ). The consistent findings across these diverse instruments further strengthened the study’s conclusions. Addressing Long-Standing Concerns: A Public Health Imperative The public health landscape surrounding COVID-19 vaccination, particularly for pregnant individuals, has been complex and often fraught with misinformation. From the early days of vaccine rollout, pregnant individuals were initially excluded from clinical trials, leading to a cautious approach to recommendations. However, as real-world data emerged demonstrating both the safety and efficacy of mRNA vaccines in this population, major health organizations, including the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal-Fetal Medicine (SMFM), swiftly moved to recommend vaccination for all individuals who are pregnant, breastfeeding, trying to get pregnant now, or might become pregnant in the future. These recommendations were based on accumulating evidence that COVID-19 infection during pregnancy posed significant risks to both mother and fetus, including increased rates of severe illness, preterm birth, and stillbirth. The benefits of vaccination—reducing severe disease, hospitalization, and death—were deemed to far outweigh any theoretical risks. Despite these clear guidelines, vaccine hesitancy among pregnant populations remained a challenge, often fueled by concerns about novel vaccine technologies and unsubstantiated fears about long-term effects on child development, including autism. The current study directly confronts one of the most persistent and emotionally charged of these concerns: the alleged link between vaccines and autism. Historically, the debunked connection between the MMR vaccine and autism, propagated by a fraudulent 1998 study, has left a lasting scar on public trust in vaccines. The emergence of new vaccine technologies, such as mRNA, for COVID-19, inadvertently created fertile ground for similar anxieties to resurface, despite the scientific community’s robust rejection of such claims. This new research serves as a critical counter-narrative, offering concrete, data-driven reassurance. The Science Behind the Safety: mRNA Vaccines in Pregnancy In the United States, two primary types of COVID-19 vaccines have been recommended: the messenger ribonucleic acid (mRNA) vaccine (from Pfizer-BioNTech and Moderna) and a protein subunit vaccine (from Novavax). Both are widely considered safe and effective for use throughout all stages of pregnancy. mRNA vaccines work by delivering a small piece of genetic code (mRNA) that instructs the body’s cells to produce a harmless piece of the SARS-CoV-2 spike protein. This protein then triggers an immune response, producing antibodies that protect against future infection. Crucially, the mRNA does not enter the nucleus of the cell, where DNA is stored, and is rapidly degraded by the body, meaning it cannot alter a person’s genetic material or be passed on to the fetus in a way that would cause developmental harm. The scientific consensus, now further bolstered by this study, confirms that these vaccines do not cross the placental barrier in a manner that would expose the fetus to vaccine components capable of causing neurodevelopmental damage. Instead, protective antibodies generated by the mother’s immune system do cross the placenta, offering passive immunity to the newborn, which has been shown to provide protection against COVID-19 infection in infants. This dual benefit—maternal protection and infant immunity—underscores the importance of vaccination during pregnancy. Expert Commentary and Reaffirmation The scientific community has reacted positively to the study’s findings, recognizing their significance in a landscape still navigating vaccine hesitancy. Dr. Brenna L. Hughes, MD, MSc, Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, commented on the robust nature of the research. "This study, conducted through a rigorous scientific process within an NIH clinical trials network, demonstrates reassuring findings regarding the long-term health of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes noted. Her statement highlights the credibility imparted by the study’s affiliation with a National Institutes of Health (NIH) network, a hallmark of high-quality clinical research. Public health organizations are expected to integrate these findings into their ongoing communication strategies, reinforcing existing recommendations and directly addressing parental concerns. For expectant parents, these results offer profound relief and clear guidance, enabling them to make informed decisions about their health and the health of their future children with greater confidence. Medical professionals, particularly obstetricians, gynecologists, and pediatricians, will find this data invaluable in counseling their patients, providing evidence-based reassurance against prevalent anxieties. Broader Implications for Maternal and Child Health The implications of this study extend beyond merely debunking a specific myth. It contributes significantly to the broader understanding of vaccine safety in pregnancy, an area historically under-researched due to ethical considerations. The methodology employed—prospective, multi-center, and observational with rigorous matching and comprehensive developmental assessments—sets a high standard for future research into vaccine and medication safety during pregnancy. By definitively ruling out a link between mRNA COVID-19 vaccines and autism or other developmental disorders, the study empowers healthcare providers to advocate for vaccination with even greater certainty. This enhanced confidence can lead to increased vaccine uptake among pregnant individuals, ultimately contributing to better maternal and infant health outcomes by reducing the burden of severe COVID-19 disease in this vulnerable population. Furthermore, these findings could help to rebuild trust in public health institutions and vaccine science, which has been eroded by misinformation campaigns over recent years. The ongoing monitoring of children born to vaccinated mothers will continue to be important, but this initial long-term data provides a critical foundation. It helps to shift the focus from unfounded fears to the proven benefits of vaccination, ensuring that discussions about maternal health interventions are grounded in scientific evidence. The study also serves as a testament to the safety and efficacy of mRNA vaccine technology itself, potentially paving the way for its broader application in addressing other infectious diseases or health conditions during pregnancy. Funding and Future Directions The significant undertaking of this research was made possible through funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health. The authors duly noted that while the study was funded by NICHD, the conclusions presented are their own and do not necessarily reflect the official views or endorsement of the National Institutes of Health. This standard disclosure maintains scientific independence and objectivity. The oral abstract detailing these crucial findings, titled "#8 Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," is slated for publication in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. Its publication in such a prestigious journal will ensure wide dissemination within the scientific and medical communities, further solidifying its impact. While this study offers substantial reassurance, ongoing vigilance and continued research remain essential. Future studies may explore even longer-term outcomes, delve into potential effects on other health parameters, and continue to monitor the evolving landscape of vaccine technologies and infectious diseases. For now, however, the message is clear and unequivocal: mRNA COVID-19 vaccines are a safe choice for pregnant individuals, offering protection without compromising the neurodevelopmental health of their children. Post navigation This common vaccine cuts heart risk nearly in half in new study
